- Global Pharma News & Resources

Oncimmune showcases early lung cancer test at ATS 2019

De Soto, KS, USA – 17 May 2019 – Oncimmune Holdings plc (AIM: ONC.L) will showcase EarlyCDT® Lung at the American Thoracic Society International Conference (ATS 2019, Dallas, TX; 17-22 May 2019). On booth #909, delegates can discover how this test can help pulmonologists assess malignancy risk in patients presenting with indeterminate pulmonary nodules (IPNs) with the aim of improving patient outcomes through earlier intervention.   Oncimmune is a leading provider of immunodiagnostics for the screening, detection and care of cancer. Oncimmune is passionate about supporting clinicians in their efforts to diagnose cancer earlier. EarlyCDT Lung, one of Oncimmune’s flagship patented in-vitro diagnostic products, was developed using disease-specific biomarker panels and immunoassay technology to provide an effective, non-invasive blood test for the early detection of all types of lung cancer with high accuracy.   Globally, lung cancer is by far the leading cause of cancer deaths [1] and this year it is estimated that there will be 228,150 new cases of lung and bronchus cancer in the US alone [2]. Late stage detection of lung cancer has a 5-year survival rate of 5%, which increases to approximately 57% if the tumour is found early while still localised [2]. There is a clinical need for new tools to help assess malignancy risk in IPNs, radiographic opacities in the lung that carry some risk of cancer. Each year nearly 1.6 million Americans have an incidentally detected nodule on the lung due to the increase in computed tomography (CT) scanning [3].   The ACCP guidelines recommend clinicians estimate the probability of malignancy for patients with IPNs larger than 8 mm [4]. Without other diagnostic tools, this requires clinician judgement based on nodule appearance, patient age, smoking and other incidental findings. The EarlyCDT Lung blood test can aid pulmonologists in the risk assessment of IPNs that have an initial risk of 10-65% [5], thereby helping improve patient outcomes through earlier intervention.

Oncimmune's recent acquisition of Protagen AG further fuels its R&D pipeline and expands its library to more than 8,000 immunogenic proteins. Protagen’s high throughput SeroTag discovery platform has the capability to accelerate the expansion of Oncimmune’s IVD product portfolio to cover other indications and to fast-track Oncimmune’s immuno-profiling capabilities for the development of patient monitoring and response prediction tools. The acquisition also adds a discovery research centre in Dortmund, Germany, to the company’s global footprint with headquarters and laboratory facility in Nottingham, UK, a CLIA lab in Kansas, US, as well as offices in London, UK and Shanghai, China.   “Oncimmune is working to change how cancer is diagnosed and treated,” said Adam Hill, CEO at Oncimmune. “Whilst early detection is already improving cancer survival, we believe immuno-profiling is the next frontier to improving patient outcomes. As such, Oncimmune is also working to develop novel diagnostic tools to monitor the therapeutic outcome of patients placed on pioneering cancer treatments, as well as identifying potential adverse effects, to improve patient well-being and prognosis.”   For more information on EarlyCDT Lung,   References (accessed 17 May 2019) [1] [2] [3] [4] [5]   For media enquiries: Helen Stewart-Miller Director of PR Services BioStrata +44 (0)1223 627120
  About Oncimmune Beating cancer, one test at a time Oncimmune is a leader in the development, manufacture and commercialisation of cancer-specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both autoimmune disease and immuno-oncology. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune’s tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.   Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT Lung is being used in what Oncimmune believes to be the largest randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and a representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.   What is EarlyCDT Lung? A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.   For more information, visit

Editor Details

Last Updated: 20-May-2019